Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells

Zhao, Hongjuan; Flamand, V.; Peehl, Donna M.

doi:10.1186/1755-8794-2-55

Cited by 31 publications

(39 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, MAOA was reported as a novel decision maker in apoptosis and autophagy processes occurring within hormone refractory neuroendocrine prostate cancer cells (28). Moreover, clorgyline, a MAOA inhibitor, was found to exhibit anti-oncogenic and pro-differentiation effects on high-grade prostate cancer cells (29), and the MAOA inhibitor-near-infrared dye conjugate was reported to reduce prostate tumor growth (30). These findings suggest that MAOA might play a key role in mediating prostate cancer progression.…”

Section: Discussionmentioning

confidence: 84%

“…Recently, several studies have been focusing on the relationship between MAOA expression and cancers (24-32). However, conflicting results were reported across different types of cancer, including prostate cancer (24)(25)(26)(27)(28)(29)(30), HCC (31), and cholangiocarcinoma (32). MAOA was demonstrated as being highly expressed in high-grade aggressive prostate cancer, and capable of mediating prostate tumorigenesis and metastasis (24)(25)(26)(27).…”

Section: Discussionmentioning

confidence: 99%

“…The functions of MAOA have been extensively studied in the context of neurological disorders, including mental depression, aggressive behaviors, and Parkinson's disease (22,23). Recent studies have indicated the role of MAOA in the progression of prostate cancer (24)(25)(26)(27)(28)(29)(30), hepatocellular carcinoma (HCC) (31), and cholangiocarcinoma (32). High Gleason grade or poorly differentiated prostate cancer exhibited increased MAOA expression (24), and the increased MAOA promoted prostate cancer metastasis (25,26 (25).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer

Liu

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Monoamine oxidase A (MAOA), a mitochondrial enzyme, is closely associated with neurological disorders. Recently, MAOA has been linked to the progression of prostate cancer, hepatocellular carcinoma, and cholangiocarcinoma. However, MAOA was reported to have different effects on the progression of these types of cancer, and the role of MAOA in non-small cell lung cancer (NSCLC) progression remains unclear. The present study determined the expression of MAOA and epithelial to mesenchymal transition (EMT) markers in 45 pairs of NSCLC and matched non-tumor adjacent lung tissues, and further analyzed the correlation between MAOA expression and the EMT or the development of clinicopathological features. The results demonstrated that protein and mRNA expression levels of MAOA in NSCLC tissues were higher than those observed in the matched non-tumor adjacent lung tissues. Furthermore, the increased MAOA expression in NSCLC tissues was positively correlated with N-cadherin (r=0.525, P=0.002), Slug (r=0.515, P=0.001), and Twist (r=0.448, P= 0.008) expressions, but negatively correlated with E-cadherin expression (r=-0.387, P=0.01). Additionally, the elevated MAOA expression in NSCLC tissues was associated with late stage NSCLC (Z=-2.596, P=0.029) and lymph node metastases (Z=-2.378, P= 0.020). These findings suggest that MAOA may have a role in promoting NSCLC progression by mediating EMT. IntroductionLung cancer, the leading cause of cancer-related deaths worldwide, is commonly divided into two categories, small cell lung cancer (SCLC) and non-SCLC (NSCLC), depending on its degree of differentiation and morphological characteristics (1,2). NSCLC accounts for ~80% of primary lung cancers, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma (3). The 5-year survival rate of NSCLC is only 7% (4). Moreover, lymph nodes and distant organ metastasis are the main reasons leading to treatment failure in NSCLC patients with radical resection (5,6).Epithelial to mesenchymal transition (EMT), a reversible biological process, is characterized by the loss of epithelial cell junction proteins (E-cadherin, Zo-1) (7,8), the gain of mesenchymal markers (vimentin, N-cadherin) (9,10), and the activation of transcription factors (Snail1, Slug, ZEB1, Twist) (11-15). Accumulating evidence indicates that EMT enhances tumor invasion, distant metastasis, and chemotherapy resistance in NSCLC, underscoring the need for a comprehensive understanding of the EMT function in NSCLC progression (16)(17)(18)(19).Monoamine oxidase A (MAOA), a mitochondria-bound enzyme, catalyzes the oxidative deamination of dietary amines and monoamine neurotransmitters, such as serotonin, norepinephrine, and dopamine (20,21). The functions of MAOA have been extensively studied in the context of neurological disorders, including mental depression, aggressive behaviors, and Parkinson's disease (22,23

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer

Liu

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…The authors identified a correlation between MAO-A inhibition and the severity of the disease according to the Gleason grading system for prostate adenocarcinoma (True et al, 2006). In-vitro experiments demonstrated that treatment of high grade prostatic cancer cells (VCaP) derived in 2001 from a patient with androgen-independent prostate cancer (PCa) with the MAO-A-selective inhibitor clorgyline slowed the tumor growth and induced transcriptome changes on genes involved in oncogenesis and differentiation (Korenchuk et al, 2001;Zhao, Flamand, & Peehl, 2009). The authors concluded that MAO-A expression in high-grade PCa might have a direct role in maintaining the de-differentiated phenotype and increases aggressive behaviour of the cancer cells.…”

Section: Other Diseasesmentioning

confidence: 99%

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Entzeroth¹,

Ratty²

2017

OJD

View full text Add to dashboard Cite

Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of major depressive disorders and treatment-resistant depression, they became less a therapeutic choice for the physicians mostly due to severe side effects, such as liver failure and hypertensive crisis associated specifically with the first generation of inhibitors. Nevertheless, this class of drugs is still being used for treatment specifically as more selective and reversible inhibitors became available and will provide clinicians with additional treatment options. The current review revisits monoamine oxidase inhibitors and their potential in the treatment of human diseases, such as anxiety, depression, mood and personality disorders, and pain and introduces current ideas and developments.

show abstract

“…Task 15: Repeat Tasks 10-13 for two additional proteins (months [24][25][26][27][28][29][30][31][32][33][34]. Due to the failure of ELISA specificity, we evaluated the Luminex system for the utilization of single- Figure 4.…”

Section: Objective 1b Ihc Analysis/confirmation Of Protein Expressiomentioning

confidence: 99%

Exploiting a Molecular Gleason Grade for Prostate Cancer Therapy

Nelson¹

2010

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. (From -To) 15 Feb 2007 -14 Feb 2010 REPORT DATE (DD-MM-YYYY) 01-03-2010 REPORT TYPE Final DATES COVERED TITLE AND SUBTITLE Exploiting a Molecular Gleason Grade for Prostate Cancer Therapy PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Fred Hutchinson Cancer Research Center PERFORMING ORGANIZATION REPORT NUMBERSeattle, WA 98109-1024 SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland SPONSOR/MONITOR'S REPORT 21702-5012 NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for public release; distribution unlimited SUPPLEMENTARY NOTES ABSTRACTThe Purpose of this proposal is to exploit a molecular correlate of the Gleason grading system for prostate carcinoma in order to: a) develop improved outcome predictors; and b) identify therapeutic strategies. During this project period we have evaluated 37 prostate cancer antigens by Western blot and tissue-based assays and identified 15 with detectable levels in the plasma. Serum levels of osteopontin discriminated men with highly advanced cancer. Tissue levels of MAOA associated with relapse after prostatectomy. We determined that major challenge for the evaluation of all candidate outcome-associated proteins centers on the lack of antibodies with suitable performance characteristics of specificity and sensitivity. This limitation impacts both tissue (IHC) and ELISA-based studies of protein localization and quantitation. Newer technologies for protein quantitation such as SISCAPA and MRM may address these limitations, but they require additional optimization. References……………………………………………………………………………. 9 Appendices…………………………………………………………………………… 9Nelson-PC060595-Progress Report 03/2010-Year 3-FINAL 4 INTRODUCTIONThis proposal was designed to exploit a molecular correlate of the Gleason grading system for prostate carcinoma in order to: a) develop improved outcome predictors; and b) identify therapeutic strategies targeted toward features unique to aggressive cancers. We hypothesized that the specific molecular features that underlie prostate cancer grades define the...

show abstract

Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells

Cited by 31 publications

References 48 publications

Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer

Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Exploiting a Molecular Gleason Grade for Prostate Cancer Therapy

Contact Info

Product

Resources

About